That's why primary efficacy endpoints looked at both short-term use (10 ± 4 days) and long-term use (35 ± 4 days).
Nevertheless, the disparate treatment duration of the two drugs adds a confounding element to the data analysis. This is probably a good thing for Lovenox insofar as it makes it harder for the trial to have an unquestionably positive outcome for Apixaban.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.